Dravet syndrome ennox-Gastaut syndrome Epidiolex Epidyolex European Commission Germany NASDAQ United Kingdom
The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In…
News
September 23
Epidiolex GW Pharmaceuticals
GW Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the British company’s…
News
July 26
Epidiolex GW Pharmaceuticals medical marijuana Sativex
United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with…
News
May 6
Cesamet Dravet syndrome Epidiolex Lennox-Gastaut syndrome Marinol Ministry of Food and Drug Safety multiple sclerosis Sativex Singapore South Korea
A groundbreaking law legalizing medical cannabis in South Korea that takes effect March 12 will pave the way for the…
News
February 19
cbd dea Epidiolex GW Pharmaceuticals LeafLogix
The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that…
News
September 27
Cesamet Epidiolex Israel Korean Cannabis Association Marinol Sativex South Korea Tikun Olam York Bridge Capital
A move to legalize medical marijuana in South Korea picked up a key backer, increasing its chances of…
News
July 24
Arizona marijuana cannabis extracts Epidiolex FDA CBD federal marijuana law U.S. Senate
The FDA signs off on a cannabis-derived drug to treat epilepsy, an Arizona court says marijuana extracts are…
News
June 29
dea Epidiolex FDA GW Pharmaceuticals
The U.S. Food and Drug Administration has approved a CBD drug - a landmark decision that will trigger…
News
June 25
Epidiolex GW Pharmaceuticals U.S. Food and Drug Administration
A CBD treatment for epilepsy is closer to becoming the first cannabis medicine approved for the U.S. market.
News
April 19